What this evidence supports
ARPA-H PROSPR is explicitly building biomarkers, trial methods, and therapeutics aimed at extending healthspan.
What it does not establish
Program success depends on milestone achievement; endpoints and interventions remain investigational.
Record details
- Source authority
- ARPA-H
- Evidence level
- E5
- Directness
- 5/5
- Recency
- 4/5
- Decision relevance
- 5/5
- Date
- 2026-02-24
Primary source
https://arpa-h.gov/news-and-events/research-teams-add-more-healthy-years-americans-lives-they-age
Related intelligence
ARPA-H awards seven PROSPR teams and up to $144M to accelerate healthspan trials